A Study With CIT-013 in HS Patients

Study acronym: Citylights
StatusActive, Not Recruiting
PhasePhase 2
SponsorCitryll BV
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Final enrollment: 108 participants (planned 96)
    • Eligibility criteria expanded, about 11 words
    • Site details revised at 28 of 28 sites
  2. Trial sites expanded: 24 → 28 locationsv6
  3. Site details revised at 9 of 24 sitesv5
  4. Study sites: 2 to 24
    • Eligibility criteria expanded, about 43 words
    v4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 2
    • Start date changed from estimate of Sep 2025 to Oct 31, 2025
    v3
  6. Secondary endpoints: details revised at 1 of 2 entriesv2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn if CIT-013 works to treat Hidradenitis Suppurativa in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are: Does CIT-013 lower the disease activity of HS patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of HS. Participants will: Take receive 50 or 100 mg CIT-013 or placebo every other week for 12 weeks Visit the clinic once every 2 weeks for checkups and tests Keep monitor their symptoms during this period
Trial Details
NCT Number NCT06993233
Lead Sponsor Citryll BV
Conditions
(from sponsor)		 Hidradenitis Suppurativa (HS)
Related terms Hidradenitis Suppurativa
Enrollment 108 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov